EGFR and non-small cell lung carcinoma: Collectively, the data indicate that concurrent activation of MET-driven bypass signaling at baseline in EGFRM+ NSCLC is an event capable of immediately interfering with the efficacy of EGFR-TKIs but can also represent a potential therapeutic co-target for combinatorial first-line strategies aimed at overcoming EGFR-TKI resistance.